MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejcts/ezad095

Медицинская библиотека · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2023

Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study.

Abdelshafy Mahmoud, Caliskan Kadir, Simpkin Andrew J, Elkoumy Ahmed, Kimman Jesse R, Elsherbini Hagar, Elzomor Hesham, de By Theo M M H, Gollmann-Tepeköylü Can, Berchtold-Herz Michael, Loforte Antonio, Reineke David, Schoenrath Felix, Paluszkiewicz Lech, Gummert Jan, Mohacsi Paul, Meyns Bart, Soliman Osama

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality.

METHODS

The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort.

RESULTS

In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2- 5.5) vs 2 (2- 4); P < 0.001], received more right ventricular assist devices (RVAD) [32 (8%) vs 178 (5.5%); P = 0.038] and stayed longer in the intensive care unit post-LVAD implant [19 (8-35) vs 11(5-25); P < 0.001]. Yet, there was no significant difference in the rate of RHF, 30-day, or 1-year mortality. Also, in the matched cohort (357 patients taking levosimendan compared to an average of 622 controls across 20 imputations), we found no evidence for a difference in postoperative severe RHF, RVAD implant rate, length of stay in the intensive care unit or 30-day and 1-year mortality.

CONCLUSIONS

In this analysis of the EUROMACS registry, we found no evidence for an association between levosimendan and early RHF or death, albeit patients taking levosimendan had much higher risk profiles. For a definitive conclusion, a multicentre, randomized study is warranted.

Для цитирования: Abdelshafy Mahmoud, Caliskan Kadir, Simpkin Andrew J, Elkoumy Ahmed, Kimman Jesse R, Elsherbini Hagar, Elzomor Hesham, de By Theo M M H, Gollmann-Tepeköylü Can, Berchtold-Herz Michael, Loforte Antonio, Reineke David, Schoenrath Felix, Paluszkiewicz Lech, Gummert Jan, Mohacsi Paul, Meyns Bart, Soliman Osama. Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study.. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2023. DOI: 10.1093/ejcts/ezad095.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.